Maraviroc for HIV: Responses at 48 Weeks

September 20, 2007

AudioMedica News

00:00 /

Jacob Lalezari

REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.

[audio:https://www.audiomedica.com/podcasting/general_medicine/070918JacobLalezari.mp3]

Tagged as:antimicrobial hiv icaac infection jacob lalezari maraviroc

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

May 28, 2020

Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...

General Medicine

Audio Journal of Medicine

May 20, 2008

AudioMedica News Audio Journal of Medicine Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds 00:00 /...

General Medicine

Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer

March 21, 2008

AudioMedica News Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer Play Episode Pause Episode Mute/Unmute...

General Medicine

New Targets Bring Promise For Lung Cancer Therapy

March 17, 2008

AudioMedica News New Targets Bring Promise For Lung Cancer Therapy Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward...

General Medicine

Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors

March 17, 2008

AudioMedica News Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors Play Episode Pause Episode Mute/Unmute Episode Rewind...

General Medicine

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

February 27, 2008

AudioMedica News Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma? Play Episode Pause Episode Mute/Unmute Episode Rewind 10 Seconds 1x...

Maraviroc for HIV: Responses at 48 Weeks

Further reading

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

Audio Journal of Medicine

Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer

New Targets Bring Promise For Lung Cancer Therapy

Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors

Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

Menu

Sign up for AudioMedica.com news